ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.
Biomed Pharmacother
; 113: 108661, 2019 May.
Article
in En
| MEDLINE
| ID: mdl-30836275
ABSTRACT
Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-ß (Aß) peptides are formed by amyloid-ß precursor protein (AßPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAßPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Plant Extracts
/
Catechin
/
Neuroprotective Agents
/
Amyloid Precursor Protein Secretases
/
Alzheimer Disease
/
ADAM10 Protein
/
Membrane Proteins
Limits:
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
2019
Document type:
Article